Skip to main content
. Author manuscript; available in PMC: 2017 Oct 28.
Published in final edited form as: J Control Release. 2016 Jan 7;240:323–331. doi: 10.1016/j.jconrel.2016.01.007

Figure 1.

Figure 1

(A) Progression of fibrotic tissue formation caused by chronic inflammation or by incompatibility of biomaterial implants; (B) EP-3533, a Gd-bearing collagen-targeted MRI contrast agent (reprinted with permission from Ref. 55); (C) In vivo molecular imaging of pulmonary (top panel) and liver fibrosis (bottom panel) using EP-3533 (reprinted with permission from Ref. 59 and 60).